Intensity Therapeutics Inc (NASDAQ: INTS)’s stock price has gone rise by 22.16 in comparison to its previous close of 0.39, however, the company has experienced a 31.63% increase in its stock price over the last five trading days. prnewswire.com reported 2025-05-29 that SHELTON, Conn., May 29, 2025 /PRNewswire/ — Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company will be presenting a Trials in Progress poster outlining its Phase 3 INVINCIBLE-3 clinical trial of INT230-6 for the treatment of metastatic soft tissue sarcomas.
Is It Worth Investing in Intensity Therapeutics Inc (NASDAQ: INTS) Right Now?
The stock has a 36-month beta value of 4.10. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for INTS is 10.02M, and at present, short sellers hold a 1.57% of that float. On June 02, 2025, the average trading volume of INTS was 340.20K shares.
INTS’s Market Performance
INTS’s stock has seen a 31.63% increase for the week, with a -19.20% drop in the past month and a -79.69% fall in the past quarter. The volatility ratio for the week is 12.51%, and the volatility levels for the past 30 days are at 9.20% for Intensity Therapeutics Inc The simple moving average for the past 20 days is 3.43% for INTS’s stock, with a -81.10% simple moving average for the past 200 days.
INTS Trading at -59.84% from the 50-Day Moving Average
After a stumble in the market that brought INTS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.68% of loss for the given period.
Volatility was left at 9.20%, however, over the last 30 days, the volatility rate increased by 12.51%, as shares sank -14.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -74.99% lower at present.
During the last 5 trading sessions, INTS rose by +31.63%, which changed the moving average for the period of 200-days by -89.15% in comparison to the 20-day moving average, which settled at $0.4594. In addition, Intensity Therapeutics Inc saw -73.00% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for INTS
The total capital return value is set at -34.94. Equity return is now at value -298.57, with -194.04 for asset returns.
Based on Intensity Therapeutics Inc (INTS), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -98.04.
Currently, EBITDA for the company is -16.24 million with net debt to EBITDA at 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
To sum up, Intensity Therapeutics Inc (INTS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
